type: insight tags: [mrr, free-trial, leading-indicator, subscription, saas, comp-distortion, policy-change] confidence: medium created: 2026-04-03 source: SHOP earnings-review Q4_FY25 persona: atlas provenance: legacy source_analysis_path: null source_paragraph_quote: null source_transcript_span: null source_loss_log_path: null

Free Trial Policy Changes Create Temporary MRR Divergence — Not a Structural Signal

When a subscription platform introduces or materially extends free trials, MRR temporarily decouples from revenue growth: free trial merchants contribute GMV and transaction revenue (Merchant Solutions) but not MRR. This inflates the revenue growth rate relative to MRR growth, creating an apparent bearish divergence in the subscription leading indicator. The divergence is a measurement artifact, not evidence of structural slowdown in merchant acquisition.

The key diagnostic: if a large MRR/revenue gap opens in the same quarter a trial policy change was announced, treat the divergence as comp-distorted until the trial cohort anniversaries (typically 3-12 months post-rollout). Only if the gap persists post-anniversary does it signal genuine acquisition weakness.

Evidence

• SHOP Q1 FY25: Shopify introduced 3-month free trials (previously 14 days). MRR growth troughed at 9.5% in Q2 FY25 while revenue grew 31.1% — a -21.6pp gap, the widest in the dataset.
• The divergence was not structural: cohort performance remained healthy (CFO confirmed 2024 and 2025 cohorts are "larger and more productive than prior cohorts").
• MRR began re-accelerating to 15.2% in Q4 FY25 as trials converted to paid plans. CFO confirmed comp headwind normalises from Q2 FY26 (when trial cohorts start anniversarying).
• Revenue growth stayed 30%+ throughout the entire divergence period, confirming underlying demand was unimpaired.

Implication

When analysing any SaaS or subscription platform, check for recent trial policy changes (length, pricing, feature gates) before interpreting MRR/ARR deceleration as structural. The correct framework:

1. Identify the policy change date — if MRR deceleration coincides with or follows a trial extension, assume artifact until proven otherwise.
2. Anniversary the cohort — divergence should narrow as the free trial window closes. If it doesn't narrow within 2 quarters of expected anniversary, escalate concern.
3. Cross-check with cohort productivity — management commentary on cohort performance is a direct read on whether converted merchants are healthy, regardless of the timing artifact in reported MRR.
4. Watch for reacceleration window — the quarter when trial comps normalize is a known catalyst; if MRR doesn't re-accelerate to near-revenue-growth rates within 1-2 quarters of comp normalization, the thesis weakens structurally.